NCT07412743

Brief Summary

School-based health centers (SBHCs) are an important setting to improve health through detecting, managing and preventing chronic illness. Too few people are educated about the human papillomavirus (HPV), which can prevent tens of thousands of deaths from cancer each year. PEER will evaluate a program to increase health and wellness and the use of SBHCs for primary and preventive care. If successful, PEER could significantly increase the use of SBHCs, and decrease HPV-associated cancers and, thus, reduce the burden of cancer in the United States.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for not_applicable

Timeline
37mo left

Started Jan 2026

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress9%
Jan 2026Jun 2029

Study Start

First participant enrolled

January 12, 2026

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

February 6, 2026

Completed
11 days until next milestone

First Posted

Study publicly available on registry

February 17, 2026

Completed
2.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2028

Expected
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2029

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

2.6 years

First QC Date

February 6, 2026

Last Update Submit

April 24, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Rate of Vaccination for HPV (n of patients with HPV vaccination/n of patients eligible for vaccination)

    Vaccination among eligible clinic patients, and time to vaccination

    6 and 12 months

Secondary Outcomes (3)

  • Rates of new patients to the clinic (n of new patients/n of established patients)

    6 and 12 months

  • Rate of use of other SBHC services (primary care visits, wellness assessments) (n of patients with primary care visits/n of new and established patients)

    6 and 12 months

  • Rate of vaccination for other adolescent vaccinations (COVID-19, flu, Meningitis, or uptick of other vax's (TDAP, MMR, etc.)) (n of patients with additional vaccination among new and eligible clinic patients)

    6 and 12 months

Study Arms (2)

Control time (pre-implementation)

NO INTERVENTION

All participating SBHCs offer routine HPV vaccination recommendations as part of clinical care and SBHC staff will continue to follow standard procedures to deliver these services. Further, all SBHCs have existing relationships with the affiliated schools, so the delivery of these healthcare services in the context of schools will not deviate from usual care.

Intervention (post-implementation)

EXPERIMENTAL

Intervention components (mailers, provider materials, and peer-to-peer educational sessions) will be administered during the intervention portion of each cluster.

Behavioral: MailersBehavioral: Provider MaterialsBehavioral: Peer-to-Peer Educational Sessions

Interventions

MailersBEHAVIORAL

Letter and fact sheet (infographic) mailed to caregivers of 9-14 year-olds and to teens 15-18, with optional phone call for "confidential patients" aged 15-18.

Intervention (post-implementation)

Clinic team/staff training based on qualitative interviews, recommended strategies and evidence-based interventions. Training materials include FAQs and Smart phrases. FAQs and informational sheets containing the same content as the mailers distributed in clinic to teen SBHC patients and their caregivers.

Intervention (post-implementation)

Educational sessions delivered in schools by OSBHA interns. Session content includes SBHC information and HPV awareness.

Intervention (post-implementation)

Eligibility Criteria

Age9 Years - 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Aged 9-18
  • New or established patients
  • Flagged if due for an HPV vaccine

You may not qualify if:

  • \- None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kaiser Permanente Center for Health Research

Portland, Oregon, 97227, United States

Location

Study Officials

  • Amanda Petrik, PhD

    Kaiser Permanente

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
CROSSOVER
Model Details: The PEER study is a concurrent stepped wedge and patient randomized trial that will take place in 9 School Based Health Centers (SBHCs) in Oregon serviced by Multnomah County Health Department (MC) clinics. All clusters start in control and cross over in a randomized, staggered fashion, with all eventually receiving the intervention.
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2026

First Posted

February 17, 2026

Study Start

January 12, 2026

Primary Completion (Estimated)

August 1, 2028

Study Completion (Estimated)

June 1, 2029

Last Updated

May 1, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Deidentified data and accompanying data dictionaries will be stored for future sharing as anonymized data sets in a data repository per NIH data sharing requirements.

Locations